Durgical
EN
Open the app

Parkinson disease dementia

Thinking slowly fails years after Parkinson disease began, often with visions of people or animals; some common medicines can make it far worse.

Updated

What it is

Dementia that develops in a person with established Parkinson disease, usually many years after the motor signs began. Lewy body (alpha-synuclein) disease spreads from the brainstem into limbic and cortical areas and causes a decline led by attention, executive and visuospatial deficits, often with visual hallucinations.

Who gets it

Dementia affects roughly 25 to 40% of people living with Parkinson disease at any time, and the risk keeps rising with time: in one cohort followed from diagnosis, over 80% of survivors had dementia after 20 years. It usually appears about 10 to 15 years after motor onset, and older age is the most consistent risk factor.

Causes

  • Spread of alpha-synuclein (Lewy body) pathology from the brainstem into limbic and neocortical areas
  • Marked loss of cortical acetylcholine from degeneration of basal forebrain cholinergic neurons
  • Coexisting Alzheimer-type changes (amyloid plaques, tau tangles) in many patients, which add to the decline
  • Dopamine loss in frontal-striatal circuits, which slows thinking and impairs planning

Risk factors

  • Older age
  • Longer duration and greater severity of Parkinson disease
  • Postural instability and gait difficulty (rigid, akinetic type) rather than tremor-dominant disease
  • Mild cognitive impairment in Parkinson disease
  • Visual hallucinations before dementia
  • Excessive daytime sleepiness and REM sleep behaviour disorder

Pathophysiology

Misfolded alpha-synuclein forms Lewy bodies and neurites that spread from the lower brainstem and substantia nigra upward into the basal forebrain, limbic system and neocortex. Degeneration of cholinergic neurons removes acetylcholine from the cortex, impairing attention and contributing to hallucinations, while dopamine loss in frontal-striatal circuits slows thinking and damages planning and set shifting. Posterior cortical and visual pathway involvement explains the visuospatial deficits and well-formed visual hallucinations. Memory fails mainly at retrieval, so cues help, unlike the storage failure of Alzheimer disease, although Alzheimer-type changes coexist in many patients. The same fragile dopamine reserve explains why dopamine-blocking antipsychotics can provoke severe rigidity and confusion.

Classification

  • Parkinson disease with mild cognitive impairment: measurable decline without loss of independence
  • Possible and probable Parkinson disease dementia (Movement Disorder Society criteria)
  • Dementia with Lewy bodies: dementia before, with or within one year of parkinsonism (the one-year rule)
  • Lewy body dementias: the umbrella term for both Parkinson disease dementia and dementia with Lewy bodies

Symptoms and signs

  • Slowed thinking with poor and fluctuating attention and concentration
  • Executive problems: planning, switching tasks, managing medicines and money
  • Visuospatial difficulty: judging distances, copying figures, drawing a clock, getting lost
  • Forgetfulness with poor free recall that improves with cues
  • Recurrent, well-formed visual hallucinations (people, animals), a sense of a presence nearby or figures passing at the edge of vision
  • Delusions in some, such as strangers living in the house or being persecuted
  • Apathy, depression, anxiety and daytime sleepiness
  • Language relatively preserved, with worsening gait, balance and falls

Diagnosis

Clinical
Clinical diagnosis: a decline in cognition from the person's previous level, severe enough to impair daily life and not explained by motor or autonomic disability, arising in established Parkinson disease. Deficits in at least two of attention, executive function, visuospatial function and free recall, without prominent language problems, support it, as do hallucinations, delusions, apathy, mood change or daytime sleepiness. A history from an informant is essential, and delirium must be excluded first.
Tests
Bedside screening (for example the Montreal Cognitive Assessment) and, when unclear, formal neuropsychological testing that allows for motor slowness. Blood tests for reversible contributors: thyroid function, vitamin B12 and folate, kidney and liver function, anaemia, and syphilis or HIV when risk factors exist. Review every medicine, especially anticholinergics, dopamine agonists, amantadine, sedatives and opioids. Certainty is only possible at autopsy.
Imaging
MRI (or CT) shows no specific pattern; it is used to exclude vascular disease, hydrocephalus, tumour or an atypical parkinsonism. Dopamine transporter imaging is abnormal in both Parkinson disease dementia and dementia with Lewy bodies, so it cannot separate them.

Differential diagnosis

  • Dementia with Lewy bodies
  • Alzheimer disease, alone or mixed with Lewy body disease
  • Delirium from infection, dehydration or medicines
  • Depression with slowed thinking
  • Vascular dementia and vascular parkinsonism
  • Progressive supranuclear palsy and other atypical parkinsonisms
  • Normal pressure hydrocephalus
  • Drug-induced hallucinations or confusion (anticholinergics, dopamine agonists, amantadine)

Dementia with parkinsonism: which one?

FeatureParkinson disease dementiaDementia with Lewy bodiesAlzheimer disease
What comes firstParkinsonism, with dementia more than a year later (often 10 to 15 years)Dementia before, with or within a year of parkinsonismMemory loss; parkinsonism absent or late and mild
Earliest thinking problemAttention, executive and visuospatialAttention, executive and visuospatial, with marked fluctuationsLearning and storing new memories, then language
Memory patternPoor free recall that improves with cuesSimilar retrieval patternRecall not rescued by cues
Visual hallucinationsCommon, usually after years of diseaseEarly and very common, a core featureUncommon, usually late
Antipsychotic sensitivitySevereSevereLess marked, though risks remain

Goal of treatment

No treatment slows the disease; care aims to improve thinking and hallucinations modestly, keep movement as good as possible without worsening confusion, prevent falls and delirium, and support the patient and caregivers.

Treatment

Medical
Cholinesterase inhibitors: rivastigmine has the strongest trial evidence, with modest gains in cognition and often greater benefit in patients who hallucinate; donepezil and other agents of the class are also used. Nausea and vomiting are the usual side effects. Memantine has shown small, inconsistent benefits.
Medical
For hallucinations or delusions: first look for infection, dehydration or a new drug, then simplify antiparkinsonian treatment, stopping anticholinergics, amantadine and dopamine agonists before reducing levodopa. Antipsychotics are a last resort: typical agents are avoided; quetiapine or pimavanserin (where available) are used.
Medical
Depression is usually treated with a selective serotonin reuptake inhibitor; tricyclic antidepressants are avoided because their anticholinergic effect worsens confusion.
Rehabilitation
Physiotherapy for gait and balance, occupational therapy for home safety, and speech and swallowing therapy.
Conservative
Bright, familiar surroundings with clocks and calendars, a steady routine, caregiver education and respite, and early advance care planning while the patient can still take part.
Follow-up
Regular review of cognition, hallucinations, falls, lying and standing blood pressure, swallowing and every new medicine, especially anticholinergics, sedatives and antipsychotics.

Complications

Common traps

  • Any dementia with parkinsonism is Parkinson disease dementia: if dementia starts before, with or within a year of the motor signs, it is dementia with Lewy bodies; Parkinson disease dementia needs more than a year of established Parkinson disease first
  • Hallucinations in Parkinson disease just mean the levodopa dose is too high: drugs must be reviewed, but in a patient with cognitive decline hallucinations are often part of the dementia itself and predict it
  • Haloperidol is a quick fix for agitation and hallucinations: dopamine-blocking antipsychotics can cause severe rigidity, confusion, falls and neuroleptic malignant syndrome in Lewy body disease
  • A memory word list is enough to screen for it: the earliest losses are attention, planning and visuospatial skills, and recall improves with cues, so tests of those domains are needed
  • Cholinesterase inhibitors only help Alzheimer disease: the cholinergic loss in Parkinson disease dementia is marked, and rivastigmine gave modest but real benefits in a large trial

Prognosis

Progressive and incurable. Dementia brings faster motor decline, more falls, more residential care and higher mortality; in one community cohort, younger-onset patients with dementia lived on average about 7.5 years compared with 12.4 years for those without dementia.

Prevention

  • No proven prevention; early recognition of mild cognitive impairment allows planning
  • Avoiding anticholinergic and sedating drugs reduces episodes of confusion
  • Prompt treatment of infection, dehydration and constipation prevents delirium

Test yourself

Think of the answer, then tap the question to see it.

A man with Parkinson disease for 12 years now gets lost, cannot plan his medicines and sees children in the garden. Is this dementia with Lewy bodies or Parkinson disease dementia?

Parkinson disease dementia. Parkinsonism preceded dementia by far more than a year; under the one-year rule, dementia before or within a year of the motor signs would be dementia with Lewy bodies.

Why is haloperidol dangerous for hallucinations in Parkinson disease dementia?

The dopamine system is already depleted; blocking what is left can cause severe rigidity, confusion, falls and neuroleptic malignant syndrome. Causes are sought first, drugs simplified, and only selected agents used.

Which cognitive domains are typically affected first in Parkinson disease dementia, and how does memory differ from Alzheimer disease?

Attention, executive and visuospatial function. Memory fails mostly at retrieval, so cues help; in Alzheimer disease new memories are not stored, so cues do little.

Hallucinations start suddenly in a patient with Parkinson disease dementia. What should be done before any antipsychotic?

Look for delirium (infection, dehydration, a new drug), then stop anticholinergics, amantadine and dopamine agonists before lowering levodopa. Antipsychotics are a last resort.

What is the rationale for cholinesterase inhibitors in Parkinson disease dementia?

Degeneration of basal forebrain cholinergic neurons leaves a marked cortical acetylcholine deficit. Rivastigmine improved cognition modestly in a large trial, often more in patients with hallucinations.

Add to my cards (5)

Connections

Educational information, not medical advice. For any symptom, see a health professional.

Sources: Dementia with Lewy Bodies and Parkinson Disease Dementia (MSD Manual Professional Edition, 2026); Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management (Frontiers in Neurology (Europe PMC), 2012).

← All conditions

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.